Actively Recruiting
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Led by UCB Biopharma SRL · Updated on 2026-04-13
300
Participants Needed
41
Research Sites
209 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
CONDITIONS
Official Title
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years of age inclusive, at the time of signing the informed consent form (ICF)
- Have a palmoplantar pustulosis (PPP) diagnosis for at least 24 weeks prior to the Screening Visit
- Have PPPASI 12 at the Screening Visit and Baseline Visit
- Have PPP-IGA �b53 at the Screening Visit and Baseline Visit
- Have pustules on the palms of the hands and/or soles of the feet at the Screening Visit and Baseline Visit, defined as pustule severity �b52 and having more than 5 active pustules
- Participant must be a candidate for systemic therapy or phototherapy
You will not qualify if you...
- Has PPP symptoms which improve significantly between the Screening Visit and Baseline Visit, defined as a reduction in the PPPASI score
- Has the following: palmoplantar PSO (plaque PSO on palms/soles), guttate PSO, erythrodermic PSO (EP), generalized pustular PSO (GPP), Acrodermatitis continua of Hallopeau (ACH), atopic dermatitis, dyshidrotic eczema or chronic hand eczema
- Has drug-induced PSO (eg, first onset or current exacerbation due to beta blockers, calcium channel inhibitors, lithium, or tumor necrosis factor [TNF] inhibitor) or drug-induced pustular PSO (eg, acute generalized exanthematous pustulosis, acute localized exanthematous pustulosis)
- Has cutaneous lesions that may interfere with the evaluation of the affected area and/or evaluation of the severity of PPP
- Is taking or has taken prohibited or restricted medications without meeting the mandatory discontinuation or stability period relative to the Baseline Visit
- Is taking or has ever taken an interleukin (IL)-17A/IL-17F inhibitor, including bimekizumab, or has participated in a bimekizumab investigational study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 41 locations
1
Ppp001 50233
Barrie, Canada
Actively Recruiting
2
Ppp001 50749
Fredericton, Canada
Actively Recruiting
3
Ppp001 50765
London, Canada
Actively Recruiting
4
Ppp001 50740
Québec, Canada
Actively Recruiting
5
Ppp001 50752
Red Deer, Canada
Actively Recruiting
6
Ppp001 50750
Surrey, Canada
Actively Recruiting
7
Ppp001 20357
Beijing, China
Actively Recruiting
8
Ppp001 20137
Chengdu, China
Actively Recruiting
9
Ppp001 20352
Chengdu, China
Actively Recruiting
10
Ppp001 20350
Chongqing, China
Actively Recruiting
11
Ppp001 20313
Guangzhou, China
Actively Recruiting
12
Ppp001 20022
Hangzhou, China
Actively Recruiting
13
Ppp001 20355
Jinan, China
Actively Recruiting
14
Ppp001 20345
Shanghai, China
Actively Recruiting
15
Ppp001 20184
Shenzhen, China
Actively Recruiting
16
Ppp001 20136
Tianjin, China
Actively Recruiting
17
Ppp001 20356
Xi'an, China
Actively Recruiting
18
Ppp001 40886
Hellerup, Denmark
Actively Recruiting
19
Ppp001 40875
Ahaus, Germany
Actively Recruiting
20
Ppp001 40740
Bad Bentheim, Germany
Actively Recruiting
21
Ppp001 40893
Bochum, Germany
Actively Recruiting
22
Ppp001 40356
Dresden, Germany
Actively Recruiting
23
Ppp001 40866
Göttingen, Germany
Actively Recruiting
24
Ppp001 40249
Kiel, Germany
Actively Recruiting
25
Ppp001 40895
Debrecen, Hungary
Actively Recruiting
26
Ppp001 40894
Orosháza, Hungary
Actively Recruiting
27
Ppp001 40816
Brescia, Italy
Actively Recruiting
28
Ppp001 40567
Roma, Italy
Actively Recruiting
29
Ppp001 40637
Gdansk, Poland
Actively Recruiting
30
Ppp001 40915
Krakow, Poland
Actively Recruiting
31
Ppp001 40757
Poznan, Poland
Actively Recruiting
32
Ppp001 40396
Rzeszów, Poland
Actively Recruiting
33
Ppp001 40743
Szczecin, Poland
Actively Recruiting
34
Ppp001 40604
Warsaw, Poland
Actively Recruiting
35
Ppp001 40625
Warsaw, Poland
Actively Recruiting
36
Ppp001 40862
Wroclaw, Poland
Actively Recruiting
37
Ppp001 40750
Alicante, Spain
Actively Recruiting
38
Ppp001 40888
Madrid, Spain
Actively Recruiting
39
Ppp001 40297
Manises, Spain
Actively Recruiting
40
Ppp001 40889
Málaga, Spain
Actively Recruiting
41
Ppp001 40880
London, United Kingdom
Actively Recruiting
Research Team
U
UCB Cares
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here